Cyclooxygenase-2 Expression in Bladder Cancer: Correlation with Poor Outcome after Chemotherapy

European Urology

Volumn 45, Issue 1, 2004, Pages 46-52

  Wülfing, Christian ^a   Eltze, Elke ^a   Von Struensee, Dagmar ^a   Wülfing, Pia ^a   Hertle, Lothar ^a   Piechota, Hansjürgen ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Biological markers; Bladder neoplasms; Cisplatin; Cyclooxygenase inhibitors; Immunohistochemistry

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR;

ADULT; AGED; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CONFERENCE PAPER; CYSTECTOMY; CYTOTOXICITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0346749443     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.08.007     Document Type: Conference Paper

References (22)

1. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol 2001;19:666.
2. Dimopoulos MA, Galani E. Randomized trials of adjuvant and neoadjuvant chemotherapy in bladder cancer. Semin Urol Oncol 2001;19:59.
3. Gately S. The contributions of cyclooxygenase-2 to tumour angiogenesis. Cancer Metastasis Rev 2000;19:19.
4. Thun MJ, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593.
5. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493.
6. Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002;13:127.
7. Kim YB, Kim GE, Cho NH, Pyo HR, Shim SJ, Chang SK, et al. Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002;95:531.
8. Ferrandina G, Lauriola L, Distefano MG, Zannoni GF, Gessi M, Legge F, et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J Clin Oncol 2002;20:973.
9. Ferrandina G, Lauriola L, Zannoni GF, Fagotti A, Fanfani F, Legge F, et al. Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients. Ann Oncol 2002;13:1205.
10. Komhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, et al. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 2000;157:29.
11. Ristimaki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001;158:849.
12. Shirahama T. Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res 2000;6:2424.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
14. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1936;50:163.
15. Cox DR. Regression models and life tables. J Roy Stat Soc B 1972;34:187.
16. Shirahama T, Sakakura C. Overexpression of cyclooxygenase-2 in squamous cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:558.
17. Yoshimura R, Sano H, Mitsuhashi M, Kohno M, Chargui J, Wada S. Expression of cyclooxygenase-2 in patients with bladder carcinoma. J Urol 2001;165:1468.
18. Kishi K, Petersen S, Petersen C, Hunter N, Mason K, Masferrer JL, et al. Preferential enhancement of tumour radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:1326.
19. Hida T, Kozaki K, Muramatsu H, Masuda A, Shimizu S, Mitsudomi T, et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin Cancer Res 2000;6:2006.
20. Sternberg CN, Swanson DA. Non-transitional cell bladder cancer. In: Raghavan D, Scher HI, Leibel SA, editors. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven-Publishers; 1997, p. 315-30.
21. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, et al. The mRNA expression of cyclooxygenase-2 (Cox-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 2002;18:237.
22. Ratnasinghe D, Daschner PJ, Anver MR, Kasprzak BH, Taylor PR, Yeh GC, et al. Cyclooxygenase-2, P-glycoprotein-170 and drug resistance is chemoprevention against multidrug resistance possible? Anticancer Res 2001;21:2141.